Andrea Kahlberg (Milan, Italy) talks to BLearning Peripheral at LINC 2020 (Leipzig Interventional Course; 28–31 January 2020, Leipzig, Germany) about a novel Sirolimus-eluting self-expanding Nitinol stent which Kahlberg claims “has the ability to improve the long-term results” of Superficial Femoral Artery (SFA) endovascular treatment.
Kahlberg outlines some of the main features and unique properties of the stent. He notes that one of the “unmet needs” of SFA stenting is durability over time, explaining that the Sirolimus is combined with fatty acids helps to improve the dispersion of the drug inside the arterial wall which helps improve durability.
He finally goes on to discuss the first in-human trial with the device, which enrolled 100 patients across Europe, and notes that the two year results were “very satisfactory” compared to other major trials that involved drug-eluting stents.
Subscribe to receive BLearning videos here: www.blearning.net/registration